Last $98.93 USD
Change Today +2.44 / 2.53%
Volume 3.1M
As of 8:04 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056


Phone: 41 61 324 11 11


ed $0.5 billion (on a core basis $0.5 billion) in research and development. CONSUMER HEALTH This division engages in the research, development, manufacturing, and marketing of a range of differentiated products that restore, maintain, or improve the health and well-being of consumers, as well as pets and livestock. The business of this division is conducted by various affiliated companies worldwide. This division consists of two divisions, such as OTC medicines and Animal Health. OTC offers consumer medicine. Animal Health provides veterinary products for farm and companion animals. OTC offers products designed for self-care, and the prevention of common medical conditions and ailments, to improve people's overall health and well-being. The business of OTC is conducted by various affiliated companies in approximately 50 countries. The OTC business focuses on a group of strategic global brands in major product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, and TheraFlu/NeoCitran), pain relief (Excedrin and Voltaren), digestive health (Benefiber, Prevacid24HR, and Pantoloc Control), dermatology (Lamisil and Fenistil), and smoking cessation (Habitrol/Nicotinell). Animal Health offers products and services to save, prolong, and improve animal lives, focusing on both companion and farm animals (including cultivated fish). The business of Animal Health is conducted by affiliated companies in approximately 40 countries. Primary products for companion animals include Atopica (atopic dermatitis management), Deramaxx and Onsior (pain relief), Fortekor (heart failure in dogs and chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while major farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine; CLiK, an insect growth regulator used to control blowfly strike in sheep; cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle; and Zolvix, a sheep drench. Aquaculture products include vaccines and treatments primarily used in salmon farming. Principal Markets The principal markets for Consumer Health are the U.S. and Europe. Marketing and Sales OTC: The company distributes its products through various channels, such as pharmacies, food, drug, and mass retail outlets. Animal Health: Animal Health's products are primarily prescription-only treatments for both farm and companion animals. The major distribution channel is veterinarians, either directly or through wholesalers of veterinary products. Research and Development In 2013, Consumer Health expensed $0.3 million (on a core basis $0.3 million) in research and development. Significant Events In April 2014, GlaxoSmithkline Consumer Healthcare Ltd. announced that GSK Plc and Novartis AG have entered into an agreement to create Consumer Healthcare Joint Venture to hold GSK's Consumer Healthcare business and Novartis OTC Consumer Healthcare business. In May 2014, Servier and Novartis announced the signing of a collaboration deal on the development and commercialisation of new drugs targeting cancer diseases. In June 2014, Novartis (Switzerland) has launched Ultibro Breezhaler (glykopyrronium + indacaterol) in Spain to treat chronic obstructive pulmonary disease (COPD). In July 2014, Google has announced a partnership with Novartis to develop a smart contact lens that can monitor the glucose levels in the eye. Bristol-Myers Squibb Company announced that it has partnered with Novartis to conduct a clinical trial evaluating the safety, tolerability and preliminary efficacy of combining BMY's investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies (Zykadia (ceritinib), INC280 and EGF816) from NVS. In November 2014, QIAGEN N.V. announced it has entered into a master collaboration agreement with Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $98.93 USD +2.44

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $105.03 USD -2.08
Merck & Co Inc $62.56 USD -0.26
Nestle SA SFr.70.15 CHF -0.30
Pfizer Inc $32.60 USD 0.00
Procter & Gamble Co/The $86.49 USD -3.09
View Industry Companies

Industry Analysis


Industry Average

Valuation NVS Industry Range
Price/Earnings 23.4x
Price/Sales 3.9x
Price/Book 3.3x
Price/Cash Flow 24.3x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at